Professor Philip J Johnson has been Chair of Translational Oncology at the University of Liverpool since 2012. He worked as: Senior Lecturer and Assistant Director in the Liver Unit at King's College Hospital; Professor of Clinical Oncology and Head of Department of the Chinese University of Hong Kong; Visiting professor at the Johns Hopkins University School of Medicine; Chair of Oncology and Translational Research; Director of the Cancer Research UK Clinical Trials Unit at the University of Birmingham.

His work on liver cancer has ranged widely from the clinical application of biomarkers to the development of selective Intra-arterial Radiotherapy (SIR) in the early 1990s. He is currently working on large international clinical datasets of over 200,000 cases, and parallelly developing serological models, such as ‘GALAD’, which has recently been awarded breakthrough device designation status by the FDA.   

He has over 700 publications and over 35,000 citations and he received The Nelson Fausto Award for Lifetime Contributions to Liver Cancer Science in September 2018.